Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. (APUS): 2 pipeline candidates · ~16 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
16.3 months
D/E 0.12 · 23% dilution
Lead: Phase 3
2 candidates
N/A
N/A
A transparent, data-derived signal for Apimeds Pharmaceuticals US, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$19.3M
Cash
$9.0M
Quarterly Burn
$2.1M
Runway
16.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| apitox | Preclinical |
| Apitox (Apitoxin in South Korea) | Phase 3 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
5
Total value held
$967K
| Holder | Shares | Value |
|---|---|---|
| hemenway trust co llc | 274,000 | $490K |
| vanguard capital management llc | 191,858 | $343K |
| geode capital management, llc | 40,051 | $72K |
| vanguard fiduciary trust co | 24,039 | $43K |
| two sigma securities, llc | 10,550 | $19K |
Frequently asked questions
How many drug candidates are in Apimeds Pharmaceuticals US, Inc.'s pipeline?
Apimeds Pharmaceuticals US, Inc. (APUS) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Apimeds Pharmaceuticals US, Inc.'s lead drug candidate?
Apimeds Pharmaceuticals US, Inc.'s most advanced tracked candidate is apitox (Preclinical) for Multiple Sclerosis (MS).
What is Apimeds Pharmaceuticals US, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Apimeds Pharmaceuticals US, Inc. has approximately 16.3 months of cash runway.
What is Apimeds Pharmaceuticals US, Inc.'s market capitalization?
Apimeds Pharmaceuticals US, Inc.'s market capitalization is approximately $19.3M.
Who is the CEO of Apimeds Pharmaceuticals US, Inc.?
Dr. Vinod Menon is the chief executive officer of Apimeds Pharmaceuticals US, Inc. (APUS).
Get the full picture on Apimeds Pharmaceuticals US, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.